Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:44 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma
NCT01672736 · University Health Network, Toronto · PHASE1/PHASE2 · terminated · last registry update 2018-09-13 · Multiple myeloma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The Sponsor decided to stop further manufacture the study drug 'Linsitinib' in Nov 2015.” | Open Targets' class: business administrative, logistics resources | Registry record, University Health Network, Toronto |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PSMD1 in multiple myeloma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-09-06Results posted on the registry: SWOG Cancer Research Network, Carfilzomib + Dexamethasone (NCT01903811)
- 2019-08-07Results posted on the registry: Millennium Pharmaceuticals, Inc., Ixazomib (NCT00932698)
- 2019-07-17Results posted on the registry: Millennium Pharmaceuticals, Inc., Cyclophosphamide + Ixazomib (NCT02046070)
- 2019-06-10Results posted on the registry: Millennium Pharmaceuticals, Inc., Ixazomib (NCT01830816)
- 2019-05-13Phase 3 first posted: Wuerzburg University Hospital, Elotuzumab + Carfilzomib (NCT03948035)
- 2019-05-08Phase 3 first posted: National Cancer Institute (NCI), Ixazomib Citrate + Lenalidomide (NCT03941860)
- 2019-05-07Results posted on the registry: Takeda, Ixazomib Citrate + Placebo (NCT02181413)
- 2019-04-08Results posted on the registry: Washington University School of Medicine, carfilzomib + pegylated liposomal doxorubicin (PLD) (NCT01246063)
- 2019-03-26Also stopped (withdrawn): National Cancer Institute (NCI), Dexamethasone + Ixazomib (NCT03856112)
- 2019-03-01Phase 3 first posted: Amgen, Carfilzomib + Carfilzomib (NCT03859427)
- 2018-12-13Results posted on the registry: Amgen, Carfilzomib + Dexamethasone (NCT02412878)
- 2018-11-21Phase 3 first posted: Millennium Pharmaceuticals, Inc., Ixazomib (NCT03748953)
- 2018-11-15Phase 3 first posted: PETHEMA Foundation, Lenalidomide. + Carfilzomib (NCT03742297)
- 2018-11-08Results posted on the registry: Millennium Pharmaceuticals, Inc., Ixazomib + Lenalidomide (NCT01645930)
- 2018-11-05Phase 3 first posted: University of Chicago, Carfilzomib + Lenalidomide (NCT03729804)
- 2018-10-25Phase 3 first posted: University of Leeds, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm + R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm (NCT03720041)
- 2018-08-29Phase 3 first posted: Celgene, bb2121 + Daratumumab (NCT03651128)
- 2018-07-10Results posted on the registry: University of Alabama at Birmingham, Carfilzomib + Melphalan (NCT01690143)
- 2018-06-19Phase 3 first posted: University of Leeds, Ixazomib, thalidomide, & dexamethasone (ITD) re-induction + Conventional autologous stem cell transplant (ASCT-con) (NCT03562169)
- 2018-05-14Results posted on the registry: Amgen, Carfilzomib (NCT00884312)
- 2018-01-23Results posted on the registry: Millennium Pharmaceuticals, Inc., Ixazomib + Melphalan (NCT01335685)
- 2017-11-24Also stopped (terminated): Emory University, Carfilzomib + Dexamethasone (NCT01969565)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision